Zevra Therapeutics (NASDAQ:ZVRA) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Zevra Therapeutics (NASDAQ:ZVRA - Free Report) from a hold rating to a buy rating in a research note released on Thursday.

A number of other research firms have also issued reports on ZVRA. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Canaccord Genuity Group lifted their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a research note on Thursday, March 13th. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Finally, Guggenheim upped their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Zevra Therapeutics has a consensus rating of "Buy" and a consensus price target of $22.29.

Zevra Therapeutics Price Performance

Shares of Zevra Therapeutics stock traded down $0.12 on Thursday, reaching $8.53. The company's stock had a trading volume of 170,756 shares, compared to its average volume of 643,473. The stock has a 50-day moving average price of $7.61 and a 200-day moving average price of $8.07. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76. The company has a market capitalization of $466.20 million, a P/E ratio of -4.34 and a beta of 1.87. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. The business had revenue of $20.40 million for the quarter, compared to analyst estimates of $16.96 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period last year, the company posted ($0.40) EPS. Analysts expect that Zevra Therapeutics will post -1.95 EPS for the current year.

Insiders Place Their Bets

In other news, Director John B. Bode purchased 10,000 shares of the firm's stock in a transaction on Wednesday, March 19th. The stock was purchased at an average cost of $7.96 per share, with a total value of $79,600.00. Following the purchase, the director now owns 40,000 shares in the company, valued at $318,400. This trade represents a 33.33% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock valued at $238,000 after acquiring an additional 1,812 shares in the last quarter. IFG Advisors LLC grew its position in Zevra Therapeutics by 10.0% during the 4th quarter. IFG Advisors LLC now owns 29,050 shares of the company's stock worth $242,000 after purchasing an additional 2,650 shares in the last quarter. Invesco Ltd. raised its stake in Zevra Therapeutics by 19.6% during the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company's stock valued at $153,000 after purchasing an additional 3,007 shares during the period. Corebridge Financial Inc. lifted its holdings in shares of Zevra Therapeutics by 16.9% in the fourth quarter. Corebridge Financial Inc. now owns 26,294 shares of the company's stock valued at $219,000 after purchasing an additional 3,801 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Zevra Therapeutics by 2.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company's stock worth $1,148,000 after buying an additional 3,827 shares during the period. Institutional investors own 35.03% of the company's stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.